Compare SNY & KKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNY | KKR |
|---|---|---|
| Founded | 1994 | 1976 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4B | 109.0B |
| IPO Year | N/A | 2010 |
| Metric | SNY | KKR |
|---|---|---|
| Price | $49.34 | $129.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $61.50 | ★ $152.73 |
| AVG Volume (30 Days) | 2.3M | ★ 4.5M |
| Earning Date | 10-24-2025 | 11-07-2025 |
| Dividend Yield | ★ 3.23% | 0.57% |
| EPS Growth | ★ 105.93 | N/A |
| EPS | ★ 8.67 | 2.37 |
| Revenue | ★ $53,890,648,839.00 | $22,245,686,000.00 |
| Revenue This Year | $2.37 | N/A |
| Revenue Next Year | $6.51 | $31.86 |
| P/E Ratio | ★ $11.25 | $54.68 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $44.62 | $86.15 |
| 52 Week High | $60.12 | $170.40 |
| Indicator | SNY | KKR |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 65.56 |
| Support Level | $48.89 | $119.09 |
| Resistance Level | $50.43 | $121.64 |
| Average True Range (ATR) | 0.73 | 3.95 |
| MACD | -0.15 | 1.52 |
| Stochastic Oscillator | 19.29 | 90.21 |
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
KKR is one of the world's largest alternative asset managers, with $723.2 billion in total managed assets, including $585.0 billion in fee-earning AUM, at the end of September 2025. The company has two core segments: asset management (which includes private markets—private equity, credit, infrastructure, energy, and real estate—and public markets—primarily credit and hedge/investment fund platforms) and insurance (following the firm's initial investment in, and then ultimate purchase of, Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance).